CN114671941A - 神经生长因子突变体 - Google Patents
神经生长因子突变体 Download PDFInfo
- Publication number
- CN114671941A CN114671941A CN202210214938.8A CN202210214938A CN114671941A CN 114671941 A CN114671941 A CN 114671941A CN 202210214938 A CN202210214938 A CN 202210214938A CN 114671941 A CN114671941 A CN 114671941A
- Authority
- CN
- China
- Prior art keywords
- growth factor
- nerve growth
- val
- mutant
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 title claims abstract description 132
- 102000015336 Nerve Growth Factor Human genes 0.000 title claims abstract description 131
- 229940053128 nerve growth factor Drugs 0.000 title claims abstract description 131
- 210000004027 cell Anatomy 0.000 claims description 31
- 239000002773 nucleotide Substances 0.000 claims description 28
- 125000003729 nucleotide group Chemical group 0.000 claims description 28
- 239000013604 expression vector Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 10
- 208000012902 Nervous system disease Diseases 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 108060003951 Immunoglobulin Proteins 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 102000018358 immunoglobulin Human genes 0.000 claims description 7
- 239000013600 plasmid vector Substances 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000013603 viral vector Substances 0.000 claims description 6
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 5
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 5
- 208000025966 Neurological disease Diseases 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 210000002856 peripheral neuron Anatomy 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 210000002161 motor neuron Anatomy 0.000 claims description 2
- 230000017074 necrotic cell death Effects 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- 208000002193 Pain Diseases 0.000 abstract description 40
- 230000036407 pain Effects 0.000 abstract description 36
- 230000000694 effects Effects 0.000 abstract description 22
- 230000035772 mutation Effects 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 150000003839 salts Chemical class 0.000 abstract description 3
- 241000880493 Leptailurus serval Species 0.000 description 40
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 40
- 150000001413 amino acids Chemical group 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 29
- 108020004414 DNA Proteins 0.000 description 28
- KQFRUSHJPKXBMB-BHDSKKPTSA-N Ala-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)C)C(O)=O)=CNC2=C1 KQFRUSHJPKXBMB-BHDSKKPTSA-N 0.000 description 20
- IYKVSFNGSWTTNZ-GUBZILKMSA-N Ala-Val-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IYKVSFNGSWTTNZ-GUBZILKMSA-N 0.000 description 20
- KXFCBAHYSLJCCY-ZLUOBGJFSA-N Asn-Asn-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O KXFCBAHYSLJCCY-ZLUOBGJFSA-N 0.000 description 20
- MYTHOBCLNIOFBL-SRVKXCTJSA-N Asn-Ser-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MYTHOBCLNIOFBL-SRVKXCTJSA-N 0.000 description 20
- CEZSLNCYQUFOSL-BQBZGAKWSA-N Cys-Arg-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O CEZSLNCYQUFOSL-BQBZGAKWSA-N 0.000 description 20
- DTLLNDVORUEOTM-WDCWCFNPSA-N Glu-Thr-Lys Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DTLLNDVORUEOTM-WDCWCFNPSA-N 0.000 description 20
- MHHUEAIBJZWDBH-YUMQZZPRSA-N Gly-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CN MHHUEAIBJZWDBH-YUMQZZPRSA-N 0.000 description 20
- GMTXWRIDLGTVFC-IUCAKERBSA-N Gly-Lys-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMTXWRIDLGTVFC-IUCAKERBSA-N 0.000 description 20
- WCHONUZTYDQMBY-PYJNHQTQSA-N His-Pro-Ile Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WCHONUZTYDQMBY-PYJNHQTQSA-N 0.000 description 20
- ALPXXNRQBMRCPZ-MEYUZBJRSA-N His-Thr-Phe Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ALPXXNRQBMRCPZ-MEYUZBJRSA-N 0.000 description 20
- DCQMJRSOGCYKTR-GHCJXIJMSA-N Ile-Asp-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O DCQMJRSOGCYKTR-GHCJXIJMSA-N 0.000 description 20
- KGCLIYGPQXUNLO-IUCAKERBSA-N Leu-Gly-Glu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O KGCLIYGPQXUNLO-IUCAKERBSA-N 0.000 description 20
- SWCOXQLDICUYOL-ULQDDVLXSA-N Phe-His-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SWCOXQLDICUYOL-ULQDDVLXSA-N 0.000 description 20
- MJAYDXWQQUOURZ-JYJNAYRXSA-N Phe-Lys-Gln Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O MJAYDXWQQUOURZ-JYJNAYRXSA-N 0.000 description 20
- TXPUNZXZDVJUJQ-LPEHRKFASA-N Pro-Asn-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)N)C(=O)N2CCC[C@@H]2C(=O)O TXPUNZXZDVJUJQ-LPEHRKFASA-N 0.000 description 20
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 20
- SGZVZUCRAVSPKQ-FXQIFTODSA-N Ser-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N SGZVZUCRAVSPKQ-FXQIFTODSA-N 0.000 description 20
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 20
- GKMYGVQDGVYCPC-IUKAMOBKSA-N Thr-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)N GKMYGVQDGVYCPC-IUKAMOBKSA-N 0.000 description 20
- NDZYTIMDOZMECO-SHGPDSBTSA-N Thr-Thr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O NDZYTIMDOZMECO-SHGPDSBTSA-N 0.000 description 20
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 20
- JXGUUJMPCRXMSO-HJOGWXRNSA-N Tyr-Phe-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 JXGUUJMPCRXMSO-HJOGWXRNSA-N 0.000 description 20
- LIQJSDDOULTANC-QSFUFRPTSA-N Val-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N LIQJSDDOULTANC-QSFUFRPTSA-N 0.000 description 20
- MJFSRZZJQWZHFQ-SRVKXCTJSA-N Val-Met-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)O)N MJFSRZZJQWZHFQ-SRVKXCTJSA-N 0.000 description 20
- KJFBXCFOPAKPTM-BZSNNMDCSA-N Val-Trp-Val Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)=CNC2=C1 KJFBXCFOPAKPTM-BZSNNMDCSA-N 0.000 description 20
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 20
- 108010068380 arginylarginine Proteins 0.000 description 20
- 108010093581 aspartyl-proline Proteins 0.000 description 20
- 108010063431 methionyl-aspartyl-glycine Proteins 0.000 description 20
- 108010048818 seryl-histidine Proteins 0.000 description 20
- YKBHOXLMMPZPHQ-GMOBBJLQSA-N Arg-Ile-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O YKBHOXLMMPZPHQ-GMOBBJLQSA-N 0.000 description 19
- NIELFHOLFTUZME-HJWJTTGWSA-N Arg-Phe-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NIELFHOLFTUZME-HJWJTTGWSA-N 0.000 description 19
- PZXPWHFYZXTFBI-YUMQZZPRSA-N Asp-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PZXPWHFYZXTFBI-YUMQZZPRSA-N 0.000 description 19
- LHRXAHLCRMQBGJ-RYUDHWBXSA-N Gly-Glu-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CN LHRXAHLCRMQBGJ-RYUDHWBXSA-N 0.000 description 19
- URHJPNHRQMQGOZ-RHYQMDGZSA-N Leu-Thr-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(O)=O URHJPNHRQMQGOZ-RHYQMDGZSA-N 0.000 description 19
- CTBMEDOQJFGNMI-IHPCNDPISA-N Lys-His-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCCCN)N CTBMEDOQJFGNMI-IHPCNDPISA-N 0.000 description 19
- YRNBANYVJJBGDI-VZFHVOOUSA-N Thr-Ala-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)O)N)O YRNBANYVJJBGDI-VZFHVOOUSA-N 0.000 description 19
- XJFXZQKJQGYFMM-GUBZILKMSA-N Val-Cys-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)O)N XJFXZQKJQGYFMM-GUBZILKMSA-N 0.000 description 19
- 108010051242 phenylalanylserine Proteins 0.000 description 19
- KGHLGJAXYSVNJP-WHFBIAKZSA-N Asp-Ser-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O KGHLGJAXYSVNJP-WHFBIAKZSA-N 0.000 description 18
- GMXSSZUVDNPRMA-FXQIFTODSA-N Cys-Arg-Asp Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O GMXSSZUVDNPRMA-FXQIFTODSA-N 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- QFBNNYNWKYKVJO-DCAQKATOSA-N Ser-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N QFBNNYNWKYKVJO-DCAQKATOSA-N 0.000 description 16
- RWOGENDAOGMHLX-DCAQKATOSA-N Val-Lys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N RWOGENDAOGMHLX-DCAQKATOSA-N 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 208000000114 Pain Threshold Diseases 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 230000037040 pain threshold Effects 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000013641 positive control Substances 0.000 description 8
- 102220246520 rs148743497 Human genes 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 description 5
- 102220476301 Mis18-binding protein 1_K74L_mutation Human genes 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 102000046917 human NGF Human genes 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 102200090384 rs749060708 Human genes 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102220477325 Protein XRP2_F101A_mutation Human genes 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 102200074331 rs122457137 Human genes 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102220478435 Acyl-coenzyme A thioesterase 13_D65A_mutation Human genes 0.000 description 3
- 102220470190 Aryl hydrocarbon receptor repressor_R59A_mutation Human genes 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 208000004454 Hyperalgesia Diseases 0.000 description 3
- 208000035154 Hyperesthesia Diseases 0.000 description 3
- 101100404651 Mus musculus Ngf gene Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000003837 chick embryo Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 102220500037 eIF5-mimic protein 2_K32G_mutation Human genes 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 102220068520 rs202031614 Human genes 0.000 description 3
- 102200027639 rs267607256 Human genes 0.000 description 3
- 102220005411 rs35873730 Human genes 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 210000005059 placental tissue Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- MIPWEZAIMPYQST-FXQIFTODSA-N Ala-Cys-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O MIPWEZAIMPYQST-FXQIFTODSA-N 0.000 description 1
- NYDBKUNVSALYPX-NAKRPEOUSA-N Ala-Ile-Arg Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NYDBKUNVSALYPX-NAKRPEOUSA-N 0.000 description 1
- MEFILNJXAVSUTO-JXUBOQSCSA-N Ala-Leu-Thr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MEFILNJXAVSUTO-JXUBOQSCSA-N 0.000 description 1
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 201000009487 Amblyopia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000012619 Butyl Sepharose® Substances 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- QFMCHXSGIZPBKG-ZLUOBGJFSA-N Cys-Ala-Asp Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CS)N QFMCHXSGIZPBKG-ZLUOBGJFSA-N 0.000 description 1
- BLGNLNRBABWDST-CIUDSAMLSA-N Cys-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CS)N BLGNLNRBABWDST-CIUDSAMLSA-N 0.000 description 1
- KZZYVYWSXMFYEC-DCAQKATOSA-N Cys-Val-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KZZYVYWSXMFYEC-DCAQKATOSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- SOEATRRYCIPEHA-BQBZGAKWSA-N Gly-Glu-Glu Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SOEATRRYCIPEHA-BQBZGAKWSA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- 101100404649 Homo sapiens NGF gene Proteins 0.000 description 1
- GYAFMRQGWHXMII-IUKAMOBKSA-N Ile-Asp-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N GYAFMRQGWHXMII-IUKAMOBKSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- LKXANTUNFMVCNF-IHPCNDPISA-N Leu-His-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O LKXANTUNFMVCNF-IHPCNDPISA-N 0.000 description 1
- FJVJLMZUIGMFFU-BQBZGAKWSA-N Met-Asp-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FJVJLMZUIGMFFU-BQBZGAKWSA-N 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- WSTIOCFMWXNOCX-YUMQZZPRSA-N Ser-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N WSTIOCFMWXNOCX-YUMQZZPRSA-N 0.000 description 1
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 1
- XVWDJUROVRQKAE-KKUMJFAQSA-N Ser-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CC=CC=C1 XVWDJUROVRQKAE-KKUMJFAQSA-N 0.000 description 1
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 1
- XGJLNBNZNMVJRS-NRPADANISA-N Val-Glu-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O XGJLNBNZNMVJRS-NRPADANISA-N 0.000 description 1
- CELJCNRXKZPTCX-XPUUQOCRSA-N Val-Gly-Ala Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O CELJCNRXKZPTCX-XPUUQOCRSA-N 0.000 description 1
- LJSZPMSUYKKKCP-UBHSHLNASA-N Val-Phe-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 LJSZPMSUYKKKCP-UBHSHLNASA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000005709 nerve cell growth Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000008285 neurophysiological mechanism Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000036441 nociceptive stimulation Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 108010084572 phenylalanyl-valine Proteins 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000012475 sodium chloride buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003238 somatosensory effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明涉及神经生长因子突变体，属于生物制药领域。神经生长因子突变体，为序列表SEQ ID No：3至SEQ ID No：21中任意一条所示的氨基酸序列。本发明的优点在于：神经生长因子突变可以减轻疼痛副作用。
Description
本申请为申请号为201780017019.9、发明名称为“神经生长因子突变体”专利申请的分案申请。
技术领域
本发明涉及神经生长因子突变体，属于生物制药领域。
背景技术
疼痛根据其神经生理学机制可分为感受性疼痛和神经病理性疼痛两类，前者直接由伤害性刺激引起，与组织损伤或炎症反应有关，又称炎症性疼痛；后者由躯体感觉神经系统的损伤或疾病直接造成的慢性疼痛。
神经生长因子(Nerve Growth Factor，NGF)是意大利科学家Levi-Montlcini于1953年在小鼠肉瘤细胞内发现的第一个神经营养因子，NGF是一种具有神经元营养和促进突起生长双重生物学功能的一种神经细胞生长调节因子，它对中枢及周围神经元的发育、分化、生长、再生和功能特性的表达均具有重要的调控作用。NGF包含α、β、γ三个亚单位，β亚单位是活性区，由两条单链通过非共价键结合而成。Levi-Montalcini因为发现了NGF而获得了诺贝尔奖。目前，国内外已有多个NGF产品上市，临床上主要用于治疗神经系统发育不良，包括弱视、神经瘤、各种神经损伤及神经系统病变等疾病。
NGF存在于多种物种中，在雄性小鼠颌下腺、牛精浆、蛇毒、豚鼠前列腺和人胎盘组织中含量丰富。其中小鼠NGF与人NGF氨基酸序列同源性达到90％。考虑到鼠NGF应用于人体的种属差异性及小鼠作为原材料所具有的潜在的致病因子风险及人胎盘组织原材料的限制，发展基因工程技术制备重组人NGF(rhNGF，recombinant human NGF)来取代提取的鼠NGF和人NGF具有很好的应用前景。
体内成熟的NGF以同源二聚体的形式存在，每条肽链包含120个氨基酸。人NGF基因位于1号染色体短臂上，完整的NGF外显子由241个氨基酸组成，通常称为prepro NGF前体，在内质网中prepro NGF前体的信号肽被切割下来，形成pro NGF前体(223个氨基酸)，proNGF前体在内质网中以同源二聚体形式存在，然后转移至高尔基体中，前体部分经Furin酶切，形成成熟的NGF二聚体(单体含有120个氨基酸)，被转运至细胞外，同时也有部分未经切割的pro NGF前体分泌至细胞外。
重组人源NGF虽然避免了一些潜在的致病风险，但在实际使用过程中仍然会存在很大问题：1)保持NGF生物活性，像其他蛋白质一样，NGF的生物活性依赖于其二级和三级结构，故在制备、纯化、存储及给药期间过程中保持其生物活性特别重要；2)NGF使用过程中会引起较严重的疼痛，部分病人无法耐受，故造成了使用上的部分受限。NGF参与了疼痛的病理生理过程，通过影响炎症介质的释放、离子通道的开放及促进神经纤维的生长导致疼痛，并通过调控离子通道及分子信号从而参与疼痛的发生发展。有学者推测NGF还可能通过促进致痛物质的表达导致疼痛，并在机体损伤后可改变神经元的出芽和再生。目前的研究发现：在人类中，不会引起痛觉过敏的最大剂量为0.03μg/kg(Pettyet al.,1994--29)。但是，如此低的剂量限制了NGF的应用，同时也限制了其适应症的扩大，如用于中枢神经系统。
因此，为避免上述问题，需寻求一种可以减轻疼痛副作用甚至无痛的重组hNGF，从而可加大使用剂量及受试人群，为扩大适应症以及应用于中枢神经系统提供了可能。
发明内容
本发明的目的是提供一系列可以减轻疼痛副作用甚至无痛的神经生长因子突变体，即重组hNGF。更优选地，提供一系列生物活性高且可以减轻疼痛副作用甚至无痛的神经生长因子突变体。为实现上述目的，本发明采用以下技术方案：
一种神经生长因子突变体，其特征在于，相对于亲本神经生长因子，所述突变体的突变位点包括：Phe12Glu、Lys32Gly、Lys32Leu、Lys32Tyr、Arg59Leu、Arg59Ala、Asp65Ala、Asp65Gly、Lys74Leu、Lys88Phe、Lys88Leu、Lys88Glu、Lys88Gly、Gln96Glu、Arg114Val、Arg114Phe、Arg114Gly、Arg114Leu、Phe101Ala或上述突变位点的任意组合；优选地，相对于亲本人神经生长因子；优选地，相对于亲本野生型人神经生长因子。
所述的神经生长因子突变体，为序列表SEQ ID No：3至SEQ ID No：21中任意一条所示的氨基酸序列。
编码所述的神经生长因子突变体的核苷酸序列。
所述的核苷酸序列，为序列表SEQ ID No：22至SEQ ID No：40所示的核苷酸序列。
本发明所述重组hNGF突变体是在野生型hNGF序列基础上进行单点突变得到的，其氨基酸序列及对应的编码核苷酸序列如下：
Phe12Glu：氨基酸序列为SEQ ID No：3，编码核苷酸序列为SEQ ID No：22；
Lys32Gly：氨基酸序列为SEQ ID No：4，编码核苷酸序列为SEQ ID No：23；
Lys32Leu：氨基酸序列为SEQ ID No：5，编码核苷酸序列为SEQ ID No：24；
Lys32Tyr：氨基酸序列为SEQ ID No：6，编码核苷酸序列为SEQ ID No：25；
Arg59Leu：氨基酸序列为SEQ ID No：7，编码核苷酸序列为SEQ ID No：26；
Arg59Ala：氨基酸序列为SEQ ID No：8，编码核苷酸序列为SEQ ID No：27；
Asp65Ala：氨基酸序列为SEQ ID No：9，编码核苷酸序列为SEQ ID No：28；
Asp65Gly：氨基酸序列为SEQ ID No：10，编码核苷酸序列为SEQ ID No：29；
Lys74Leu：氨基酸序列为SEQ ID No：11，编码核苷酸序列为SEQ ID No：30；
Lys88Phe：氨基酸序列为SEQ ID No：12，编码核苷酸序列为SEQ ID No：31；
Lys88Leu：氨基酸序列为SEQ ID No：13，编码核苷酸序列为SEQ ID No：32；
Lys88Glu：氨基酸序列为SEQ ID No：14，编码核苷酸序列为SEQ ID No：33；
Lys88Gly：氨基酸序列为SEQ ID No：15，编码核苷酸序列为SEQ ID No：34；
Gln96Glu：氨基酸序列为SEQ ID No：16，编码核苷酸序列为SEQ ID No：35；
Arg114Val：氨基酸序列为SEQ ID No：17，编码核苷酸序列为SEQ ID No：36；
Arg114Phe：氨基酸序列为SEQ ID No：18，编码核苷酸序列为SEQ ID No：37；
Arg114Gly：氨基酸序列为SEQ ID No：19，编码核苷酸序列为SEQ ID No：38；
Arg114Leu：氨基酸序列为SEQ ID No：20，编码核苷酸序列为SEQ ID No：39；
Phe101Ala：氨基酸序列为SEQ ID No：21，编码核苷酸序列为SEQ ID No：40。
一种长效化神经生长因子突变体，其中所述长效化神经生长因子突变体是由上述任意所述的氨基酸序列得到的。
优选地，所述长效化神经生长因子突变体是通过化学修饰得到的，优选地所述长效化神经生长因子突变体为聚乙二醇和神经生长因子突变体的结合物。
优选地，所述长效化神经生长因子突变体是与其他蛋白融合得到的融合蛋白。优选地所述蛋白为人白蛋白，人白蛋白类似物，人白蛋白的片段，免疫球蛋白的Fc部分，免疫球蛋白的Fc部分的类似物，或免疫球蛋白的Fc部分的片段。
优选地所述融合蛋白为神经生长因子突变体的C末端直接或通过肽接头与白蛋白或Fc蛋白的N末端融合得到的。
一种表达载体，含有所述的核苷酸序列。
所述表达载体选自由DNA载体和病毒载体所组成的组中。
所述DNA载体选自由DNA质粒载体、结合其的脂质体、结合其的分子耦联体和结合其的多聚物所组成的组中；优选地，所述DNA质粒载体为真核细胞表达载体；所述病毒载体选自由腺相关病毒载体、慢病毒载体和腺病毒载体所组成的组中。
一种表达所述表达载体的方法，将所述的表达载体转染至宿主细胞，培养所得重组细胞表达得到神经生长因子突变体。
含有所述表达载体的宿主细胞。
所述的宿主细胞为哺乳动物细胞。
所述哺乳动物细胞为中国仓鼠卵巢细胞、人胚肾293细胞、COS细胞或Hela细胞。
一种药物组合物，所述药物组合物含有药学上可接受的赋形剂，以及上述提及的神经生长因子突变体、上述提及的表达载体和上述提及的宿主细胞中的一种或几种。
本发明的药物可以制成注射剂、胶囊、片剂或粉剂等多种形式，上述各种剂型的药物均可以按照药学领域的常规方法制备。
所述药物组合物优选为注射液，所述注射液包括药学上可接受的赋形剂以及上述提及的神经生长因子突变体。
需要的时候，在上述药物组合物中还可以加入一种或多种药学上可接受的载体，所述载体包括药学领域常规的稀释剂、稳定剂、表面活性剂和防腐剂等。
所述的神经生长因子突变体用于制备治疗神经系统疾病的药物中的用途。所述神经系统疾病指与神经元退化或损伤相关的中枢和/或外周神经系统的疾病。神经系统疾病的具体例子包括但并不限于：Alzheimer病、Parkinson病、Huntington舞蹈病、中风、ALS、外周神经病变和其他特征为神经元坏死或丧失的病症，无论是中枢的、外周的还是运动神经元(motorneuron)，除了治疗因外伤、烧伤、肾衰竭或受伤造成的神经损伤之外。例如，与某些病症相关的外周神经病变如与糖尿病、AIDS或化疗相关的神经病变。
将神经生长因子突变体制备得到治疗神经系统疾病的药物可用于给病人施用。确切的使用剂量将取决于被治疗的疾病，而且可由该领域的技术人员用已知技术确定。另外，如本领域中所知，需要根据年龄、体重、一般健康状况、性别、饮食、施用时间、药物相互作用和疾病严重程度等情况加以调节，这可由该领域的技术人员通过常规试验而确定。此处提及的病人包括人和其他动物及生物体。因此，这些方法可用于人的治疗和兽用。
本发明的由神经生长因子突变体制备得到治疗神经系统疾病的药物的施用可用多种方法进行，其中包括但并不限于：口服、皮下、静脉、脑内、鼻内、透过皮肤、腹膜内、肌内、肺内、阴道给药、直肠给药和眼内给药等。在某些情况下，比如在处理伤口时，可直接以溶液或喷雾形式施用。
本发明的药物组合物含有所述神经生长因子突变体，它处于适合给病人施用的形式。在优选例子中，药物组合物是水溶性形式，并且可以含有诸如载体、赋形剂、稳定剂、缓冲液、盐分、抗氧化剂、亲水聚合物、氨基酸、碳水化合物、离子或非离子表面活性剂、聚乙二醇或丙二醇等。所述神经生长因子突变体制备的药物也可以用本领域已知的技术以缓释形式植入，或者以微囊形式包埋。
所述的神经生长因子突变体用于制备有效减轻体重的药物中的用途。
所述的神经生长因子突变体用于制备长效化神经生长因子的用途。
本发明的优点在于：相对于现有技术中的野生型神经生长因子而言，可以减轻疼痛副作用甚至导致无痛，进一步地，部分神经生长因子突变体的生物活性会有明显提高。
以下结合附图和具体实施方式对本发明做进一步说明，并非对本发明的限定，凡依照本发明公开内容所进行的本领域等同替换，均属于本发明保护范围。
附图说明
图1为实施例4 Superdex75柱纯化的野生型hNGF的SDS PAGE电泳结果
图2(A)和图2(B)为实施例5中突变体的活性测定结果
图3(A)和图3(B)为实施例7短期给药小鼠痛阈测定结果
图4(A)、图4(B)和图4(C)为实施例7长期给药小鼠痛阈测定结果
图5为实施例8小鼠行为学实验结果，分别注射突变体、野生型hNGF，观测小鼠抬腿维持时间
具体实施方式
实施例1.野生型h NGF及其突变体的质粒构建
1、构建野生型hNGF的DNA序列表达质粒
合成野生型hNGF的DNA序列(序列表SEQ ID NO：1)，使用引物(F：GGAATTCATGTCCATGTTG(序列表SEQ ID NO：41)，R：CAAGCTTTCAGGCTCTTCT(序列表SEQ IDNO：42))对目的序列进行PCR扩增，使用EcorI(NEB#R0101S)进行酶切后，将酶切产物使用HindIII(NEB#R0104S)进行二次酶切。将pcDNA3.1(-)表达载体使用同样的方法进行酶切。将酶切载体和PCR扩增目的片段进行琼脂糖凝胶电泳，切下目的片段，使用DNA胶回收试剂盒(TIANGEN，#DP209-03)分别回收酶切后的载体和目的DNA片段后，使用DNA连接酶试剂盒(Takara/6022)16℃连接1h，完成野生型hNGF的质粒构建。
2、构建hNGF突变体的DNA序列表达质粒
同样上述方法，我们合成并构建了所有突变体的质粒。突变体的DNA序列为序列表SEQ ID No：22至SEQ ID No：40所示的核苷酸序列。
实施例2、hNGF及其突变体的质粒转化及提取
1、转化：
将上述实施例1构建好的hNGF及其突变体质粒进行热激转化，将Top10感受态细胞(天根/CB104-02)从-70℃冰箱取出后立即置于冰上解冻，取50ul用于转化。向其中加入2ul质粒，轻弹混匀，冰浴30min。于42℃干浴90s，期间不要振荡离心管，取出后立即置于冰上2min。加入无抗LB/SOC培养基500ul，150rpm/min，37℃摇床培养45min。将离心管内液体全部倒入LB平板上，均匀涂开。待平板晾干后，倒置于培养箱培养16h。
2、质粒大提
挑取上述2.1实验得到的单菌落接种于500ul LB液体培养基，37℃培养7h，同时菌液送检测序。将测序正确的菌液进行大量摇菌，将500ul菌液接种于500mlLB培养基，37℃培养16h。4℃离心收集过夜培养的菌液，6000xg离心10分钟，充分弃去上清使用质粒大提试剂盒(购自QIAGEN，货号12163)大提质粒，测量浓度备用。
实施例3.野生型hNGF及其突变体的表达
将上述实施例2大提得到的野生型hNGF和及其突变体质粒转染293F细胞中，转染后第四日收集表达上清并定量。
实验步骤：
1、转染前一天，接种293F细胞，0.5×106/ml，共900ml，300ml/瓶。
2、转染当天计数，细胞密度约1.0×106/ml，活率99％以上。
3、转染：取36ml细胞培养基到125ml培养瓶；加360ug质粒，混匀；再加1080ug PEI，混匀。室温静置15分钟；与细胞混匀，约12.3ml/瓶；37℃，8％CO2，120RPM培养。
4、转染后第四日收集细胞上清，10000g离心20分钟。
5、收集上清，0.45um过滤，得到野生型hNGF及其突变体的蛋白上清液。
6、SDS-PAGE检测，硝酸银染色定量。
实施例4.野生型hNGF及其突变体的纯化
纯化上述实施例3中得到的NGF及其突变体的蛋白上清液。
1、阳离子交换层析：先使用乙酸和水调野生型hNGF及其突变体的蛋白上清液至pH为4.0。CM Sepharose FF层析柱用0.05mol/L乙酸盐缓冲液(pH4.0)充分平衡后上样，上样完成后，用平衡液冲洗至基线，用0.05mol/L Tris-HC1(pH9.0)缓冲液洗脱杂峰至基线，再用0.05mol/LTris-HC1和0.05mol/L Tris-HC1-0.4mol/L NaCl(pH9.0)梯度洗脱，根据紫外吸收情况收集目标峰，在紫外检测仪上显示数字开始上升时开始收集，降为基线时停止收集目标蛋白峰。
2、疏水层析：Butyl Sepharose 4 FF层析柱经0.02mol/L磷酸盐(pH6.8)-1.5mol/L氯化钠缓冲液充分平衡。在步骤1收集的目标峰料液中加入氯化钠固体使料液中氯化钠的终浓度为1.5mol/L，待氯化钠充分溶解后上样，速度为120cm/h，上样完成后用平衡液冲洗至基线，然后用0.02mol/L磷酸盐(pH6.8)洗脱收集目标峰。
3、凝胶排阻层析：Superdex 75 prep grade层析柱用pH6.8、0.05mol/L磷酸盐-0.15mol/L氯化钠缓冲液充分平衡后上样步骤/2中收集的目标峰，在紫外检测仪上显示数字从基线开始上升时开始收集，降为基线时停止收集目标蛋白峰。
Superdex75柱纯化的野生型hNGF的SDS PAGE如图1所示，说明制备得到的NGF纯度较高。将收集的野生型hNGF及其突变体目标蛋白峰样品使用超滤管浓缩至0.4mg/ml，4℃保存用于后续实验。
实施例5.鸡胚法测定野生型hNGF及其突变体活性
1、鸡胚背根神经节法测量野生型hNGF及其突变体活性
将上述实施例4中得到的野生型hNGF(氨基酸序列参见序列表)及其突变体(氨基酸序列参见序列表)样品进行稀释：A液：6ng提取的野生型hNGF及其突变体样品加1ml无血清DMEM培养液溶解；B液：取A液50μl加无血清DMEM培养液4.95ml；C液：取B液60μl加无血清DMEM培养液2.94ml(总量3ml)使终浓度为(3AU/ml)。A、B液稀释在离心管中，C液在细胞瓶内，将C液作为1号瓶，再3倍梯度稀释为：2号、3号、4号、5号、6号待测液。每个待测液加入1个培养瓶，2ml/瓶。同时以无血清DMEM培养液为空白对照，以购自中检院的标准品为阳性对照(参考品)。加入8日龄的鸡胚背根神经节后置于5％CO2、37℃饱和湿度培养箱中，24小时后观察结果。
以生长最好时每毫升待测样品中NGF的含量作为1个活性单位(AU)。从出现阴性对照结果的稀释度开始往回数第3和第4两个稀释度中取生长最好的作为判定终点计算效价。参考品为购自中检院的标准品，每支装量为1000AU。
NGF比活的计算公式为：
待测样品的比活(AU/mg)＝参考品活性(AU/ml)×[样品预稀释倍数×对应参考品稀释点处的活性(AU/ml)/参考品实测活性(AU/ml)]
测活结果如图2(A)和图2(B)所示。结果表明，hNGF突变体Phe12Glu，Lys32Leu，Arg59Leu，Asp65Ala，Lys74Leu，Lys88Leu，Lys88Gly，Gln96Glu，Phe101Ala，Arg114Leu，均保留了野生型的活性，甚至活性更高。
实施例6.TF-1细胞法测定NGF及其突变体活性
详细操作方法按照专利公开号为CN103376248A，专利名称为“神经生长因子活性定量测定方法”中实施例1中的方法进行操作，比活性检测结果见下表。
表1
| 样品名称 | 细胞法比活(U/mg) |
| 野生型hNGF | 43万 |
| Lys74Leu | 76.7万 |
| Phe12Glu | 62万 |
| Lys88Gly | 59万 |
| Gln96Glu | 43万 |
实施例7.NGF及其突变体是否致痛(疼痛阈值)检测
实验原理：筛选对痛觉反应正常的合格小鼠，注射一定剂量的NGF样品(野生型或其突变体)，通过机械刺激测定小鼠曲爪反应疼痛阈值，进行统计分析，最终确定样品是否引起小鼠痛觉过敏。
7-1、短期致痛情况观测
一、实验材料
动态足底触觉仪，意大利/Ugo Basile，型号37450。
二、实验内容
1、合格小鼠筛选
订购SPF级别CD-1小鼠，小鼠规格为雄性，体重30-35g。
使用动态足底触觉仪[意大利/Ugo Basile，型号37450]筛选两足平均阈值在7.5-10之间且同一只小鼠左右脚阈值P值，P值>0.05的实验动物为合格小鼠。
随机分组，分为实验组和空白对照组，实验组又按照不同样品及给药剂量分为小组，每组10只。
2、NGF样品给药设计
2.1野生型样品致痛剂量筛选
药物配制：将阳性对照NGF野生型样品及各突变体样品均使用样品储备液(50mMPB,150mM NaCl，PH6.8)进行稀释。
空白对照：为NGF样品储备液。
给药方式及剂量：小鼠左右脚足底皮下分别给药20ul；
短期给药最低剂量为1.25μg/只，同时给予相应比较高的剂量以确定其致痛性，见图3(B)标注剂量。
3、痛阈测
在给药后分别在1个小时、2个小时进行机械阈值测定，并且记录数值，进行短期给药(2小时内)的观测。
4、结果统计分析
采用GraphPad Prism软件进行图表绘制及结果统计分析，比较各剂量组与对照组之间机械阈值是否有差异，分析野生型样品以及突变体样品的致痛性。
由图3(A)可知，给药最低剂量为1.25μg/只时，对照组小鼠无疼痛表现，而野生型的阳性对照组，疼痛阈值在1h明显低于5以下，疼痛明显；而各突变体实验组疼痛阈值均在7左右，与阴性对照组比无明显差异，说明短期注射突变体基本无致痛性；
由图3(B)可知，对照组与野生型的给药剂量为1.25μg/只，实验组给药剂量增加时，对照组小鼠无疼痛表现，而野生型的阳性对照组，疼痛阈值在1h明显低于5以下，疼痛明显；而各突变体实验组疼痛阈值均在7左右，与阴性对照组比无明显差异，说明加大给药剂量的情况下短期注射突变体也基本无致痛性。
7-2长期致痛情况观测
随机选择上述突变体中的三个1号(Phe12Glu)、2号(Lys88Gly、3号(Arg114Leu)进行长期致痛试验，除设定本次实验的3个给药剂量为：0.2μg/只、0.5μg/只、1.25μg/只，每天给药一次，连续3周，期间不间断的进行疼痛阈值的测定外，其余均按照7-1“短期致痛情况观测”中的方法进行。
结果如图4(A)、4(B)和4(C)所示，表明：突变体Phe12Glu在14天内痛阈未明显降低，未见导致疼痛，14天后仅出现中剂量(0.5ug/只)短暂的疼痛；突变体Lys88Gly、突变体Arg114Leu在试验过程中均未出现明显的痛阈改变；而野生型NGF在17天以内三个剂量显示痛阈逐渐降低，逐渐出现疼痛感。可见，本发明的突变体较野生型具有显著的降低疼痛的优点。
实施例8.野生型hNGF及其突变体是否致痛的行为学检测
野生型hNGF及其突变体样品对小鼠关节给药，通过行为学观察小鼠抬腿时间以及次数来考察样品是否致痛。
实验内容
1、小鼠订购
订购SPF级别CD-1小鼠，小鼠规格为雄性，体重30-35g。随机分组，分为实验组、空白对照组(简称对照组)及阳性对照组，各组根据剂量又分为七个小组，每个小组随机挑选6只。
2、给药剂量与时间
2.1给药剂量
阳性对照：采用样品储备液(50mM PB,150mM NaCl，PH6.8)稀释野生型hNGF为1.25μg/10ul组；
实验组：突变体药物配制方法同阳性对照，稀释突变体Phe12Glu、Lys88Gly及Arg114Leu为1.25μg/10ul组及0.5μg/10ul；
空白对照：生理盐水。
2.2给药方式
在小鼠后腿关节内注射药品，每个关节腔给药10ul。
2.3给药时间：
每剂量组进行单次连续3-4天给药。即第一天上午10点，以及之后第2、3、4天相同时间点给药。
3、行为学观察
各实验组以及对照组当天给药后2、4小时进行观察，以及给药的第2、3、4天相同时间点进行观察。
观察指标：2分钟内小鼠自发性抬腿的次数以及每次抬腿维持的时间(秒)，计算抬腿维持累计时间。
4、结果统计分析
采用GraphPad Prism软件双因素方差分析抬腿维持时间，比较分析不同样品是否致痛。
实验结果如图5所示：野生型hNGF组在注射药物后的各检测时间点均能引起明显的疼痛，突变体各剂量组连续给药均没有抬腿行为或者疼痛异常现象，可确定不引起疼痛，卡方分析得知在各检测时间点阳性对照组与实验组均有明显差异。
序列表
<110> 舒泰神（北京）生物制药股份有限公司
<120> 神经生长因子突变体
<130>
<160> 42
<170> PatentIn version 3.5
<210> 1
<211> 726
<212> DNA
<213> 人属，人种：野生型人NGF的DNA序列
<400> 1
atgtccatgt tgttctacac tctgatcaca gcttttctga tcggcataca ggcggaacca 60
cactcagaga gcaatgtccc tgcaggacac accatccccc aagcccactg gactaaactt 120
cagcattccc ttgacactgc ccttcgcaga gcccgcagcg ccccggcagc ggcgatagct 180
gcacgcgtgg cggggcagac ccgcaacatt actgtggacc ccaggctgtt taaaaagcgg 240
cgactccgtt caccccgtgt gctgtttagc acccagcctc cccgtgaagc tgcagacact 300
caggatctgg acttcgaggt cggtggtgct gcccccttca acaggactca caggagcaag 360
cggtcatcat cccatcccat cttccacagg ggcgaattct cggtgtgtga cagtgtcagc 420
gtgtgggttg gggataagac caccgccaca gacatcaagg gcaaggaggt gatggtgttg 480
ggagaggtga acattaacaa cagtgtattc aaacagtact tttttgagac caagtgccgg 540
gacccaaatc ccgttgacag cgggtgccgg ggcattgact caaagcactg gaactcatat 600
tgtaccacga ctcacacctt tgtcaaggcg ctgaccatgg atggcaagca ggctgcctgg 660
cggtttatcc ggatagatac ggcctgtgtg tgtgtgctca gcaggaaggc tgtgagaaga 720
gcctga 726
<210> 2
<211> 120
<212> PRT
<213> 人属，人种：野生型人NGF的氨基酸序列
<400> 2
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp
1 5 10 15
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys
20 25 30
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val
35 40 45
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val
50 55 60
Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys
65 70 75 80
Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln
85 90 95
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu
100 105 110
Ser Arg Lys Ala Val Arg Arg Ala
115 120
<210> 3
<211> 120
<212> PRT
<213> 人属，人种，NGF突变体 Phe12Glu
<400> 3
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Glu Ser Val Cys Asp
1 5 10 15
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys
20 25 30
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val
35 40 45
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val
50 55 60
Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys
65 70 75 80
Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln
85 90 95
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu
100 105 110
Ser Arg Lys Ala Val Arg Arg Ala
115 120
<210> 4
<211> 120
<212> PRT
<213> 人属，人种：NGF突变体Lys32Gly
<400> 4
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp
1 5 10 15
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Gly
20 25 30
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val
35 40 45
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val
50 55 60
Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys
65 70 75 80
Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln
85 90 95
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu
100 105 110
Ser Arg Lys Ala Val Arg Arg Ala
115 120
<210> 5
<211> 120
<212> PRT
<213> 人属，人种：NGF突变体Lys32Leu
<400> 5
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp
1 5 10 15
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Leu
20 25 30
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val
35 40 45
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val
50 55 60
Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys
65 70 75 80
Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln
85 90 95
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu
100 105 110
Ser Arg Lys Ala Val Arg Arg Ala
115 120
<210> 6
<211> 120
<212> PRT
<213> 人属，人种：NGF突变体Lys32Tyr
<400> 6
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp
1 5 10 15
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Tyr
20 25 30
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val
35 40 45
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val
50 55 60
Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys
65 70 75 80
Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln
85 90 95
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu
100 105 110
Ser Arg Lys Ala Val Arg Arg Ala
115 120
<210> 7
<211> 120
<212> PRT
<213> 人属，人种：NGF突变体Arg59Leu
<400> 7
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp
1 5 10 15
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys
20 25 30
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val
35 40 45
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Leu Asp Pro Asn Pro Val
50 55 60
Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys
65 70 75 80
Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln
85 90 95
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu
100 105 110
Ser Arg Lys Ala Val Arg Arg Ala
115 120
<210> 8
<211> 120
<212> PRT
<213> 人属，人种：NGF突变体Arg59Ala
<400> 8
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp
1 5 10 15
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys
20 25 30
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val
35 40 45
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Ala Asp Pro Asn Pro Val
50 55 60
Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys
65 70 75 80
Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln
85 90 95
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu
100 105 110
Ser Arg Lys Ala Val Arg Arg Ala
115 120
<210> 9
<211> 120
<212> PRT
<213> 人属，人种：NGF突变体Asp65Ala
<400> 9
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp
1 5 10 15
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys
20 25 30
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val
35 40 45
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val
50 55 60
Ala Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys
65 70 75 80
Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln
85 90 95
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu
100 105 110
Ser Arg Lys Ala Val Arg Arg Ala
115 120
<210> 10
<211> 120
<212> PRT
<213> 人属，人种：NGF突变体Asp65Gly
<400> 10
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp
1 5 10 15
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys
20 25 30
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val
35 40 45
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val
50 55 60
Gly Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys
65 70 75 80
Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln
85 90 95
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu
100 105 110
Ser Arg Lys Ala Val Arg Arg Ala
115 120
<210> 11
<211> 120
<212> PRT
<213> 人属，人种：NGF突变体Lys74Leu
<400> 11
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp
1 5 10 15
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys
20 25 30
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val
35 40 45
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val
50 55 60
Asp Ser Gly Cys Arg Gly Ile Asp Ser Leu His Trp Asn Ser Tyr Cys
65 70 75 80
Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln
85 90 95
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu
100 105 110
Ser Arg Lys Ala Val Arg Arg Ala
115 120
<210> 12
<211> 120
<212> PRT
<213> 人属，人种：NGF突变体Lys88Phe
<400> 12
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp
1 5 10 15
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys
20 25 30
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val
35 40 45
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val
50 55 60
Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys
65 70 75 80
Thr Thr Thr His Thr Phe Val Phe Ala Leu Thr Met Asp Gly Lys Gln
85 90 95
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu
100 105 110
Ser Arg Lys Ala Val Arg Arg Ala
115 120
<210> 13
<211> 120
<212> PRT
<213> 人属，人种：NGF突变体Lys88Leu
<400> 13
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp
1 5 10 15
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys
20 25 30
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val
35 40 45
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val
50 55 60
Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys
65 70 75 80
Thr Thr Thr His Thr Phe Val Leu Ala Leu Thr Met Asp Gly Lys Gln
85 90 95
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu
100 105 110
Ser Arg Lys Ala Val Arg Arg Ala
115 120
<210> 14
<211> 120
<212> PRT
<213> 人属，人种：NGF突变体Lys88Glu
<400> 14
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp
1 5 10 15
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys
20 25 30
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val
35 40 45
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val
50 55 60
Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys
65 70 75 80
Thr Thr Thr His Thr Phe Val Glu Ala Leu Thr Met Asp Gly Lys Gln
85 90 95
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu
100 105 110
Ser Arg Lys Ala Val Arg Arg Ala
115 120
<210> 15
<211> 120
<212> PRT
<213> 人属，人种：NGF突变体Lys88Gly
<400> 15
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp
1 5 10 15
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys
20 25 30
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val
35 40 45
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val
50 55 60
Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys
65 70 75 80
Thr Thr Thr His Thr Phe Val Gly Ala Leu Thr Met Asp Gly Lys Gln
85 90 95
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu
100 105 110
Ser Arg Lys Ala Val Arg Arg Ala
115 120
<210> 16
<211> 120
<212> PRT
<213> 人属，人种：NGF突变体Gln96Glu
<400> 16
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp
1 5 10 15
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys
20 25 30
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val
35 40 45
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val
50 55 60
Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys
65 70 75 80
Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Glu
85 90 95
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu
100 105 110
Ser Arg Lys Ala Val Arg Arg Ala
115 120
<210> 17
<211> 120
<212> PRT
<213> 人属，人种：NGF突变体Arg114Val
<400> 17
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp
1 5 10 15
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys
20 25 30
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val
35 40 45
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val
50 55 60
Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys
65 70 75 80
Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln
85 90 95
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu
100 105 110
Ser Val Lys Ala Val Arg Arg Ala
115 120
<210> 18
<211> 120
<212> PRT
<213> 人属，人种：NGF突变体Arg114Phe
<400> 18
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp
1 5 10 15
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys
20 25 30
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val
35 40 45
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val
50 55 60
Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys
65 70 75 80
Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln
85 90 95
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu
100 105 110
Ser Phe Lys Ala Val Arg Arg Ala
115 120
<210> 19
<211> 120
<212> PRT
<213> 人属，人种：NGF突变体Arg114Gly
<400> 19
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp
1 5 10 15
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys
20 25 30
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val
35 40 45
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val
50 55 60
Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys
65 70 75 80
Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln
85 90 95
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu
100 105 110
Ser Gly Lys Ala Val Arg Arg Ala
115 120
<210> 20
<211> 120
<212> PRT
<213> 人属，人种：NGF突变体Arg114Leu
<400> 20
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp
1 5 10 15
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys
20 25 30
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val
35 40 45
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val
50 55 60
Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys
65 70 75 80
Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln
85 90 95
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu
100 105 110
Ser Leu Lys Ala Val Arg Arg Ala
115 120
<210> 21
<211> 120
<212> PRT
<213> 人属，人种：NGF突变体Phe101Ala
<400> 21
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp
1 5 10 15
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys
20 25 30
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val
35 40 45
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val
50 55 60
Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys
65 70 75 80
Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln
85 90 95
Ala Ala Trp Arg Ala Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu
100 105 110
Ser Arg Lys Ala Val Arg Arg Ala
115 120
<210> 22
<211> 726
<212> DNA
<213> 人属，人种：NGF突变体Phe12Glu编码基因
<400> 22
atgtccatgt tgttctacac tctgatcaca gcttttctga tcggcataca ggcggaacca 60
cactcagaga gcaatgtccc tgcaggacac accatccccc aagcccactg gactaaactt 120
cagcattccc ttgacactgc ccttcgcaga gcccgcagcg ccccggcagc ggcgatagct 180
gcacgcgtgg cggggcagac ccgcaacatt actgtggacc ccaggctgtt taaaaagcgg 240
cgactccgtt caccccgtgt gctgtttagc acccagcctc cccgtgaagc tgcagacact 300
caggatctgg acttcgaggt cggtggtgct gcccccttca acaggactca caggagcaag 360
cggtcatcat cccatcccat cttccacagg ggcgaagagt cggtgtgtga cagtgtcagc 420
gtgtgggttg gggataagac caccgccaca gacatcaagg gcaaggaggt gatggtgttg 480
ggagaggtga acattaacaa cagtgtattc aaacagtact tttttgagac caagtgccgg 540
gacccaaatc ccgttgacag cgggtgccgg ggcattgact caaagcactg gaactcatat 600
tgtaccacga ctcacacctt tgtcaaggcg ctgaccatgg atggcaagca ggctgcctgg 660
cggtttatcc ggatagatac ggcctgtgtg tgtgtgctca gcaggaaggc tgtgagaaga 720
gcctga 726
<210> 23
<211> 726
<212> DNA
<213> 人属，人种：NGF突变体Lys32Gly编码基因
<400> 23
atgtccatgt tgttctacac tctgatcaca gcttttctga tcggcataca ggcggaacca 60
cactcagaga gcaatgtccc tgcaggacac accatccccc aagcccactg gactaaactt 120
cagcattccc ttgacactgc ccttcgcaga gcccgcagcg ccccggcagc ggcgatagct 180
gcacgcgtgg cggggcagac ccgcaacatt actgtggacc ccaggctgtt taaaaagcgg 240
cgactccgtt caccccgtgt gctgtttagc acccagcctc cccgtgaagc tgcagacact 300
caggatctgg acttcgaggt cggtggtgct gcccccttca acaggactca caggagcaag 360
cggtcatcat cccatcccat cttccacagg ggcgaattct cggtgtgtga cagtgtcagc 420
gtgtgggttg gggataagac caccgccaca gacatcgggg gcaaggaggt gatggtgttg 480
ggagaggtga acattaacaa cagtgtattc aaacagtact tttttgagac caagtgccgg 540
gacccaaatc ccgttgacag cgggtgccgg ggcattgact caaagcactg gaactcatat 600
tgtaccacga ctcacacctt tgtcaaggcg ctgaccatgg atggcaagca ggctgcctgg 660
cggtttatcc ggatagatac ggcctgtgtg tgtgtgctca gcaggaaggc tgtgagaaga 720
gcctga 726
<210> 24
<211> 726
<212> DNA
<213> 人属，人种：NGF突变体Lys32Leu编码基因
<400> 24
atgtccatgt tgttctacac tctgatcaca gcttttctga tcggcataca ggcggaacca 60
cactcagaga gcaatgtccc tgcaggacac accatccccc aagcccactg gactaaactt 120
cagcattccc ttgacactgc ccttcgcaga gcccgcagcg ccccggcagc ggcgatagct 180
gcacgcgtgg cggggcagac ccgcaacatt actgtggacc ccaggctgtt taaaaagcgg 240
cgactccgtt caccccgtgt gctgtttagc acccagcctc cccgtgaagc tgcagacact 300
caggatctgg acttcgaggt cggtggtgct gcccccttca acaggactca caggagcaag 360
cggtcatcat cccatcccat cttccacagg ggcgaattct cggtgtgtga cagtgtcagc 420
gtgtgggttg gggataagac caccgccaca gacatcctgg gcaaggaggt gatggtgttg 480
ggagaggtga acattaacaa cagtgtattc aaacagtact tttttgagac caagtgccgg 540
gacccaaatc ccgttgacag cgggtgccgg ggcattgact caaagcactg gaactcatat 600
tgtaccacga ctcacacctt tgtcaaggcg ctgaccatgg atggcaagca ggctgcctgg 660
cggtttatcc ggatagatac ggcctgtgtg tgtgtgctca gcaggaaggc tgtgagaaga 720
gcctga 726
<210> 25
<211> 726
<212> DNA
<213> 人属，人种：NGF突变体Lys32Tyr 编码基因
<400> 25
atgtccatgt tgttctacac tctgatcaca gcttttctga tcggcataca ggcggaacca 60
cactcagaga gcaatgtccc tgcaggacac accatccccc aagcccactg gactaaactt 120
cagcattccc ttgacactgc ccttcgcaga gcccgcagcg ccccggcagc ggcgatagct 180
gcacgcgtgg cggggcagac ccgcaacatt actgtggacc ccaggctgtt taaaaagcgg 240
cgactccgtt caccccgtgt gctgtttagc acccagcctc cccgtgaagc tgcagacact 300
caggatctgg acttcgaggt cggtggtgct gcccccttca acaggactca caggagcaag 360
cggtcatcat cccatcccat cttccacagg ggcgaattct cggtgtgtga cagtgtcagc 420
gtgtgggttg gggataagac caccgccaca gacatctacg gcaaggaggt gatggtgttg 480
ggagaggtga acattaacaa cagtgtattc aaacagtact tttttgagac caagtgccgg 540
gacccaaatc ccgttgacag cgggtgccgg ggcattgact caaagcactg gaactcatat 600
tgtaccacga ctcacacctt tgtcaaggcg ctgaccatgg atggcaagca ggctgcctgg 660
cggtttatcc ggatagatac ggcctgtgtg tgtgtgctca gcaggaaggc tgtgagaaga 720
gcctga 726
<210> 26
<211> 726
<212> DNA
<213> 人属，人种：NGF突变体Arg59Leu编码基因
<400> 26
atgtccatgt tgttctacac tctgatcaca gcttttctga tcggcataca ggcggaacca 60
cactcagaga gcaatgtccc tgcaggacac accatccccc aagcccactg gactaaactt 120
cagcattccc ttgacactgc ccttcgcaga gcccgcagcg ccccggcagc ggcgatagct 180
gcacgcgtgg cggggcagac ccgcaacatt actgtggacc ccaggctgtt taaaaagcgg 240
cgactccgtt caccccgtgt gctgtttagc acccagcctc cccgtgaagc tgcagacact 300
caggatctgg acttcgaggt cggtggtgct gcccccttca acaggactca caggagcaag 360
cggtcatcat cccatcccat cttccacagg ggcgaattct cggtgtgtga cagtgtcagc 420
gtgtgggttg gggataagac caccgccaca gacatcaagg gcaaggaggt gatggtgttg 480
ggagaggtga acattaacaa cagtgtattc aaacagtact tttttgagac caagtgcctg 540
gacccaaatc ccgttgacag cgggtgccgg ggcattgact caaagcactg gaactcatat 600
tgtaccacga ctcacacctt tgtcaaggcg ctgaccatgg atggcaagca ggctgcctgg 660
cggtttatcc ggatagatac ggcctgtgtg tgtgtgctca gcaggaaggc tgtgagaaga 720
gcctga 726
<210> 27
<211> 726
<212> DNA
<213> 人属，人种：NGF突变体Arg59Ala编码基因
<400> 27
atgtccatgt tgttctacac tctgatcaca gcttttctga tcggcataca ggcggaacca 60
cactcagaga gcaatgtccc tgcaggacac accatccccc aagcccactg gactaaactt 120
cagcattccc ttgacactgc ccttcgcaga gcccgcagcg ccccggcagc ggcgatagct 180
gcacgcgtgg cggggcagac ccgcaacatt actgtggacc ccaggctgtt taaaaagcgg 240
cgactccgtt caccccgtgt gctgtttagc acccagcctc cccgtgaagc tgcagacact 300
caggatctgg acttcgaggt cggtggtgct gcccccttca acaggactca caggagcaag 360
cggtcatcat cccatcccat cttccacagg ggcgaattct cggtgtgtga cagtgtcagc 420
gtgtgggttg gggataagac caccgccaca gacatcaagg gcaaggaggt gatggtgttg 480
ggagaggtga acattaacaa cagtgtattc aaacagtact tttttgagac caagtgcgcg 540
gacccaaatc ccgttgacag cgggtgccgg ggcattgact caaagcactg gaactcatat 600
tgtaccacga ctcacacctt tgtcaaggcg ctgaccatgg atggcaagca ggctgcctgg 660
cggtttatcc ggatagatac ggcctgtgtg tgtgtgctca gcaggaaggc tgtgagaaga 720
gcctga 726
<210> 28
<211> 726
<212> DNA
<213> 人属，人种：NGF突变体Asp65Ala编码基因
<400> 28
atgtccatgt tgttctacac tctgatcaca gcttttctga tcggcataca ggcggaacca 60
cactcagaga gcaatgtccc tgcaggacac accatccccc aagcccactg gactaaactt 120
cagcattccc ttgacactgc ccttcgcaga gcccgcagcg ccccggcagc ggcgatagct 180
gcacgcgtgg cggggcagac ccgcaacatt actgtggacc ccaggctgtt taaaaagcgg 240
cgactccgtt caccccgtgt gctgtttagc acccagcctc cccgtgaagc tgcagacact 300
caggatctgg acttcgaggt cggtggtgct gcccccttca acaggactca caggagcaag 360
cggtcatcat cccatcccat cttccacagg ggcgaattct cggtgtgtga cagtgtcagc 420
gtgtgggttg gggataagac caccgccaca gacatcaagg gcaaggaggt gatggtgttg 480
ggagaggtga acattaacaa cagtgtattc aaacagtact tttttgagac caagtgccgg 540
gacccaaatc ccgttgccag cgggtgccgg ggcattgact caaagcactg gaactcatat 600
tgtaccacga ctcacacctt tgtcaaggcg ctgaccatgg atggcaagca ggctgcctgg 660
cggtttatcc ggatagatac ggcctgtgtg tgtgtgctca gcaggaaggc tgtgagaaga 720
gcctga 726
<210> 29
<211> 726
<212> DNA
<213> 人属，人种：NGF突变体Asp65Gly编码基因
<400> 29
atgtccatgt tgttctacac tctgatcaca gcttttctga tcggcataca ggcggaacca 60
cactcagaga gcaatgtccc tgcaggacac accatccccc aagcccactg gactaaactt 120
cagcattccc ttgacactgc ccttcgcaga gcccgcagcg ccccggcagc ggcgatagct 180
gcacgcgtgg cggggcagac ccgcaacatt actgtggacc ccaggctgtt taaaaagcgg 240
cgactccgtt caccccgtgt gctgtttagc acccagcctc cccgtgaagc tgcagacact 300
caggatctgg acttcgaggt cggtggtgct gcccccttca acaggactca caggagcaag 360
cggtcatcat cccatcccat cttccacagg ggcgaattct cggtgtgtga cagtgtcagc 420
gtgtgggttg gggataagac caccgccaca gacatcaagg gcaaggaggt gatggtgttg 480
ggagaggtga acattaacaa cagtgtattc aaacagtact tttttgagac caagtgccgg 540
gacccaaatc ccgttggcag cgggtgccgg ggcattgact caaagcactg gaactcatat 600
tgtaccacga ctcacacctt tgtcaaggcg ctgaccatgg atggcaagca ggctgcctgg 660
cggtttatcc ggatagatac ggcctgtgtg tgtgtgctca gcaggaaggc tgtgagaaga 720
gcctga 726
<210> 30
<211> 726
<212> DNA
<213> 人属，人种：NGF突变体Lys74Leu编码基因
<400> 30
atgtccatgt tgttctacac tctgatcaca gcttttctga tcggcataca ggcggaacca 60
cactcagaga gcaatgtccc tgcaggacac accatccccc aagcccactg gactaaactt 120
cagcattccc ttgacactgc ccttcgcaga gcccgcagcg ccccggcagc ggcgatagct 180
gcacgcgtgg cggggcagac ccgcaacatt actgtggacc ccaggctgtt taaaaagcgg 240
cgactccgtt caccccgtgt gctgtttagc acccagcctc cccgtgaagc tgcagacact 300
caggatctgg acttcgaggt cggtggtgct gcccccttca acaggactca caggagcaag 360
cggtcatcat cccatcccat cttccacagg ggcgaattct cggtgtgtga cagtgtcagc 420
gtgtgggttg gggataagac caccgccaca gacatcaagg gcaaggaggt gatggtgttg 480
ggagaggtga acattaacaa cagtgtattc aaacagtact tttttgagac caagtgccgg 540
gacccaaatc ccgttgacag cgggtgccgg ggcattgact cattgcactg gaactcatat 600
tgtaccacga ctcacacctt tgtcaaggcg ctgaccatgg atggcaagca ggctgcctgg 660
cggtttatcc ggatagatac ggcctgtgtg tgtgtgctca gcaggaaggc tgtgagaaga 720
gcctga 726
<210> 31
<211> 726
<212> DNA
<213> 人属，人种：NGF突变体Lys88Phe编码基因
<400> 31
atgtccatgt tgttctacac tctgatcaca gcttttctga tcggcataca ggcggaacca 60
cactcagaga gcaatgtccc tgcaggacac accatccccc aagcccactg gactaaactt 120
cagcattccc ttgacactgc ccttcgcaga gcccgcagcg ccccggcagc ggcgatagct 180
gcacgcgtgg cggggcagac ccgcaacatt actgtggacc ccaggctgtt taaaaagcgg 240
cgactccgtt caccccgtgt gctgtttagc acccagcctc cccgtgaagc tgcagacact 300
caggatctgg acttcgaggt cggtggtgct gcccccttca acaggactca caggagcaag 360
cggtcatcat cccatcccat cttccacagg ggcgaattct cggtgtgtga cagtgtcagc 420
gtgtgggttg gggataagac caccgccaca gacatcaagg gcaaggaggt gatggtgttg 480
ggagaggtga acattaacaa cagtgtattc aaacagtact tttttgagac caagtgccgg 540
gacccaaatc ccgttgacag cgggtgccgg ggcattgact caaagcactg gaactcatat 600
tgtaccacga ctcacacctt tgtctttgcg ctgaccatgg atggcaagca ggctgcctgg 660
cggtttatcc ggatagatac ggcctgtgtg tgtgtgctca gcaggaaggc tgtgagaaga 720
gcctga 726
<210> 32
<211> 726
<212> DNA
<213> 人属，人种：NGF突变体Lys88Leu编码基因
<400> 32
atgtccatgt tgttctacac tctgatcaca gcttttctga tcggcataca ggcggaacca 60
cactcagaga gcaatgtccc tgcaggacac accatccccc aagcccactg gactaaactt 120
cagcattccc ttgacactgc ccttcgcaga gcccgcagcg ccccggcagc ggcgatagct 180
gcacgcgtgg cggggcagac ccgcaacatt actgtggacc ccaggctgtt taaaaagcgg 240
cgactccgtt caccccgtgt gctgtttagc acccagcctc cccgtgaagc tgcagacact 300
caggatctgg acttcgaggt cggtggtgct gcccccttca acaggactca caggagcaag 360
cggtcatcat cccatcccat cttccacagg ggcgaattct cggtgtgtga cagtgtcagc 420
gtgtgggttg gggataagac caccgccaca gacatcaagg gcaaggaggt gatggtgttg 480
ggagaggtga acattaacaa cagtgtattc aaacagtact tttttgagac caagtgccgg 540
gacccaaatc ccgttgacag cgggtgccgg ggcattgact caaagcactg gaactcatat 600
tgtaccacga ctcacacctt tgtcttggcg ctgaccatgg atggcaagca ggctgcctgg 660
cggtttatcc ggatagatac ggcctgtgtg tgtgtgctca gcaggaaggc tgtgagaaga 720
gcctga 726
<210> 33
<211> 726
<212> DNA
<213> 人属，人种：NGF突变体Lys88Glu编码基因
<400> 33
atgtccatgt tgttctacac tctgatcaca gcttttctga tcggcataca ggcggaacca 60
cactcagaga gcaatgtccc tgcaggacac accatccccc aagcccactg gactaaactt 120
cagcattccc ttgacactgc ccttcgcaga gcccgcagcg ccccggcagc ggcgatagct 180
gcacgcgtgg cggggcagac ccgcaacatt actgtggacc ccaggctgtt taaaaagcgg 240
cgactccgtt caccccgtgt gctgtttagc acccagcctc cccgtgaagc tgcagacact 300
caggatctgg acttcgaggt cggtggtgct gcccccttca acaggactca caggagcaag 360
cggtcatcat cccatcccat cttccacagg ggcgaattct cggtgtgtga cagtgtcagc 420
gtgtgggttg gggataagac caccgccaca gacatcaagg gcaaggaggt gatggtgttg 480
ggagaggtga acattaacaa cagtgtattc aaacagtact tttttgagac caagtgccgg 540
gacccaaatc ccgttgacag cgggtgccgg ggcattgact caaagcactg gaactcatat 600
tgtaccacga ctcacacctt tgtcgaggcg ctgaccatgg atggcaagca ggctgcctgg 660
cggtttatcc ggatagatac ggcctgtgtg tgtgtgctca gcaggaaggc tgtgagaaga 720
gcctga 726
<210> 34
<211> 726
<212> DNA
<213> 人属，人种：NGF突变体Lys88Gly编码基因
<400> 34
atgtccatgt tgttctacac tctgatcaca gcttttctga tcggcataca ggcggaacca 60
cactcagaga gcaatgtccc tgcaggacac accatccccc aagcccactg gactaaactt 120
cagcattccc ttgacactgc ccttcgcaga gcccgcagcg ccccggcagc ggcgatagct 180
gcacgcgtgg cggggcagac ccgcaacatt actgtggacc ccaggctgtt taaaaagcgg 240
cgactccgtt caccccgtgt gctgtttagc acccagcctc cccgtgaagc tgcagacact 300
caggatctgg acttcgaggt cggtggtgct gcccccttca acaggactca caggagcaag 360
cggtcatcat cccatcccat cttccacagg ggcgaattct cggtgtgtga cagtgtcagc 420
gtgtgggttg gggataagac caccgccaca gacatcaagg gcaaggaggt gatggtgttg 480
ggagaggtga acattaacaa cagtgtattc aaacagtact tttttgagac caagtgccgg 540
gacccaaatc ccgttgacag cgggtgccgg ggcattgact caaagcactg gaactcatat 600
tgtaccacga ctcacacctt tgtcggggcg ctgaccatgg atggcaagca ggctgcctgg 660
cggtttatcc ggatagatac ggcctgtgtg tgtgtgctca gcaggaaggc tgtgagaaga 720
gcctga 726
<210> 35
<211> 726
<212> DNA
<213> 人属，人种：NGF突变体Gln96Glu编码基因
<400> 35
atgtccatgt tgttctacac tctgatcaca gcttttctga tcggcataca ggcggaacca 60
cactcagaga gcaatgtccc tgcaggacac accatccccc aagcccactg gactaaactt 120
cagcattccc ttgacactgc ccttcgcaga gcccgcagcg ccccggcagc ggcgatagct 180
gcacgcgtgg cggggcagac ccgcaacatt actgtggacc ccaggctgtt taaaaagcgg 240
cgactccgtt caccccgtgt gctgtttagc acccagcctc cccgtgaagc tgcagacact 300
caggatctgg acttcgaggt cggtggtgct gcccccttca acaggactca caggagcaag 360
cggtcatcat cccatcccat cttccacagg ggcgaattct cggtgtgtga cagtgtcagc 420
gtgtgggttg gggataagac caccgccaca gacatcaagg gcaaggaggt gatggtgttg 480
ggagaggtga acattaacaa cagtgtattc aaacagtact tttttgagac caagtgccgg 540
gacccaaatc ccgttgacag cgggtgccgg ggcattgact caaagcactg gaactcatat 600
tgtaccacga ctcacacctt tgtcaaggcg ctgaccatgg atggcaagga ggctgcctgg 660
cggtttatcc ggatagatac ggcctgtgtg tgtgtgctca gcaggaaggc tgtgagaaga 720
gcctga 726
<210> 36
<211> 726
<212> DNA
<213> 人属，人种：NGF突变体Arg114Val编码基因
<400> 36
atgtccatgt tgttctacac tctgatcaca gcttttctga tcggcataca ggcggaacca 60
cactcagaga gcaatgtccc tgcaggacac accatccccc aagcccactg gactaaactt 120
cagcattccc ttgacactgc ccttcgcaga gcccgcagcg ccccggcagc ggcgatagct 180
gcacgcgtgg cggggcagac ccgcaacatt actgtggacc ccaggctgtt taaaaagcgg 240
cgactccgtt caccccgtgt gctgtttagc acccagcctc cccgtgaagc tgcagacact 300
caggatctgg acttcgaggt cggtggtgct gcccccttca acaggactca caggagcaag 360
cggtcatcat cccatcccat cttccacagg ggcgaattct cggtgtgtga cagtgtcagc 420
gtgtgggttg gggataagac caccgccaca gacatcaagg gcaaggaggt gatggtgttg 480
ggagaggtga acattaacaa cagtgtattc aaacagtact tttttgagac caagtgccgg 540
gacccaaatc ccgttgacag cgggtgccgg ggcattgact caaagcactg gaactcatat 600
tgtaccacga ctcacacctt tgtcaaggcg ctgaccatgg atggcaagca ggctgcctgg 660
cggtttatcc ggatagatac ggcctgtgtg tgtgtgctca gcgtcaaggc tgtgagaaga 720
gcctga 726
<210> 37
<211> 726
<212> DNA
<213> 人属，人种：NGF突变体Arg114Phe编码基因
<400> 37
atgtccatgt tgttctacac tctgatcaca gcttttctga tcggcataca ggcggaacca 60
cactcagaga gcaatgtccc tgcaggacac accatccccc aagcccactg gactaaactt 120
cagcattccc ttgacactgc ccttcgcaga gcccgcagcg ccccggcagc ggcgatagct 180
gcacgcgtgg cggggcagac ccgcaacatt actgtggacc ccaggctgtt taaaaagcgg 240
cgactccgtt caccccgtgt gctgtttagc acccagcctc cccgtgaagc tgcagacact 300
caggatctgg acttcgaggt cggtggtgct gcccccttca acaggactca caggagcaag 360
cggtcatcat cccatcccat cttccacagg ggcgaattct cggtgtgtga cagtgtcagc 420
gtgtgggttg gggataagac caccgccaca gacatcaagg gcaaggaggt gatggtgttg 480
ggagaggtga acattaacaa cagtgtattc aaacagtact tttttgagac caagtgccgg 540
gacccaaatc ccgttgacag cgggtgccgg ggcattgact caaagcactg gaactcatat 600
tgtaccacga ctcacacctt tgtcaaggcg ctgaccatgg atggcaagca ggctgcctgg 660
cggtttatcc ggatagatac ggcctgtgtg tgtgtgctca gcttcaaggc tgtgagaaga 720
gcctga 726
<210> 38
<211> 726
<212> DNA
<213> 人属，人种：NGF突变体Arg114Gly编码基因
<400> 38
atgtccatgt tgttctacac tctgatcaca gcttttctga tcggcataca ggcggaacca 60
cactcagaga gcaatgtccc tgcaggacac accatccccc aagcccactg gactaaactt 120
cagcattccc ttgacactgc ccttcgcaga gcccgcagcg ccccggcagc ggcgatagct 180
gcacgcgtgg cggggcagac ccgcaacatt actgtggacc ccaggctgtt taaaaagcgg 240
cgactccgtt caccccgtgt gctgtttagc acccagcctc cccgtgaagc tgcagacact 300
caggatctgg acttcgaggt cggtggtgct gcccccttca acaggactca caggagcaag 360
cggtcatcat cccatcccat cttccacagg ggcgaattct cggtgtgtga cagtgtcagc 420
gtgtgggttg gggataagac caccgccaca gacatcaagg gcaaggaggt gatggtgttg 480
ggagaggtga acattaacaa cagtgtattc aaacagtact tttttgagac caagtgccgg 540
gacccaaatc ccgttgacag cgggtgccgg ggcattgact caaagcactg gaactcatat 600
tgtaccacga ctcacacctt tgtcaaggcg ctgaccatgg atggcaagca ggctgcctgg 660
cggtttatcc ggatagatac ggcctgtgtg tgtgtgctca gcgggaaggc tgtgagaaga 720
gcctga 726
<210> 39
<211> 726
<212> DNA
<213> 人属，人种：NGF突变体Arg114Leu编码基因
<400> 39
atgtccatgt tgttctacac tctgatcaca gcttttctga tcggcataca ggcggaacca 60
cactcagaga gcaatgtccc tgcaggacac accatccccc aagcccactg gactaaactt 120
cagcattccc ttgacactgc ccttcgcaga gcccgcagcg ccccggcagc ggcgatagct 180
gcacgcgtgg cggggcagac ccgcaacatt actgtggacc ccaggctgtt taaaaagcgg 240
cgactccgtt caccccgtgt gctgtttagc acccagcctc cccgtgaagc tgcagacact 300
caggatctgg acttcgaggt cggtggtgct gcccccttca acaggactca caggagcaag 360
cggtcatcat cccatcccat cttccacagg ggcgaattct cggtgtgtga cagtgtcagc 420
gtgtgggttg gggataagac caccgccaca gacatcaagg gcaaggaggt gatggtgttg 480
ggagaggtga acattaacaa cagtgtattc aaacagtact tttttgagac caagtgccgg 540
gacccaaatc ccgttgacag cgggtgccgg ggcattgact caaagcactg gaactcatat 600
tgtaccacga ctcacacctt tgtcaaggcg ctgaccatgg atggcaagca ggctgcctgg 660
cggtttatcc ggatagatac ggcctgtgtg tgtgtgctca gcttgaaggc tgtgagaaga 720
gcctga 726
<210> 40
<211> 726
<212> DNA
<213> 人属，人种：NGF突变体Phe101Ala编码基因
<400> 40
atgtccatgt tgttctacac tctgatcaca gcttttctga tcggcataca ggcggaacca 60
cactcagaga gcaatgtccc tgcaggacac accatccccc aagcccactg gactaaactt 120
cagcattccc ttgacactgc ccttcgcaga gcccgcagcg ccccggcagc ggcgatagct 180
gcacgcgtgg cggggcagac ccgcaacatt actgtggacc ccaggctgtt taaaaagcgg 240
cgactccgtt caccccgtgt gctgtttagc acccagcctc cccgtgaagc tgcagacact 300
caggatctgg acttcgaggt cggtggtgct gcccccttca acaggactca caggagcaag 360
cggtcatcat cccatcccat cttccacagg ggcgaattct cggtgtgtga cagtgtcagc 420
gtgtgggttg gggataagac caccgccaca gacatcaagg gcaaggaggt gatggtgttg 480
ggagaggtga acattaacaa cagtgtattc aaacagtact tttttgagac caagtgccgg 540
gacccaaatc ccgttgacag cgggtgccgg ggcattgact caaagcactg gaactcatat 600
tgtaccacga ctcacacctt tgtcaaggcg ctgaccatgg atggcaagca ggctgcctgg 660
cgggcgatcc ggatagatac ggcctgtgtg tgtgtgctca gcaggaaggc tgtgagaaga 720
gcctga 726
<210> 41
<211> 19
<212> DNA
<213> 人工合成引物序列F
<400> 41
ggaattcatg tccatgttg 19
<210> 42
<211> 19
<212> DNA
<213> 人工合成引物序列R
<400> 42
caagctttca ggctcttct 19
Claims (18)
1.一种神经生长因子突变体，其特征在于，所述神经生长因子突变体的氨基酸序列如SEQ ID No：20所示。
2.编码权利要求1所述的神经生长因子突变体的核苷酸序列。
3.根据权利要求2所述的核苷酸序列，其特征在于：所述核苷酸序列如SEQ ID No：39所示。
4.一种长效化神经生长因子突变体，其特征在于：所述长效化神经生长因子突变体是由所述权利要求1所述的氨基酸序列得到的。
5.根据权利要求4所述的长效化神经生长因子突变体,其特征在于：所述长效化神经生长因子突变体为聚乙二醇和神经生长因子突变体的结合物。
6.根据权利要求4所述的长效化神经生长因子突变体,其特征在于：所述长效化神经生长因子突变体是与人白蛋白、免疫球蛋白的Fc部分或免疫球蛋白的Fc部分的片段融合得到的融合蛋白；优选地所述融合蛋白为神经生长因子突变体的C末端直接或通过肽接头与人白蛋白、免疫球蛋白的Fc部分或免疫球蛋白的Fc部分的片段的N末端融合得到的。
7.一种表达载体，其特征在于：所述表达载体含有权利要求2或3所述的核苷酸序列。
8.根据权利要求7所述的表达载体，其特征在于，所述表达载体选自由DNA载体和病毒载体所组成的组中。
9.根据权利要求8所述的表达载体，其特征在于，所述DNA载体选自由DNA质粒载体、结合所述DNA质粒载体的脂质体、结合所述DNA质粒载体的分子耦联体和结合所述DNA质粒载体的多聚物所组成的组中；优选地，所述DNA质粒载体为真核细胞表达载体；所述病毒载体选自由腺相关病毒载体、慢病毒载体和腺病毒载体所组成的组中。
10.一种表达权利要求7～9中任一所述表达载体的方法，其特征在于：将所述的表达载体转染至宿主细胞，培养所得重组细胞表达得到神经生长因子突变体。
11.含有权利要求7～9中任一所述表达载体的宿主细胞。
12.根据权利要求11所述的宿主细胞，其特征在于：所述宿主细胞为哺乳动物细胞。
13.根据权利要求12所述的宿主细胞，其特征在于，所述哺乳动物细胞为中国仓鼠卵巢细胞、人胚肾293细胞、COS细胞或Hela细胞。
14.一种药物组合物，其特征在于，所述药物组合物含有药学上可接受的赋形剂，以及选自权利要求1所述的神经生长因子突变体、4～6中任何一项所述的长效化神经生长因子突变体、权利要求7～9中任何一项所述的表达载体和权利要求11～13中任何一项所述的宿主细胞中的一种或几种。
15.根据权利要求14所述的药物组合物，其特征在于，所述药物组合物为注射液，所述注射液包括药学上可接受的赋形剂以及权利要求1所述的神经生长因子突变体。
16.权利要求1所述的神经生长因子突变体用于制备治疗神经系统疾病的药物中的用途；优选地，所述神经系统疾病为与神经元退化或损伤相关的中枢和/或外周神经系统的疾病；更优选地，所述神经系统疾病包括但并不限于：Alzheimer病、Parkinson病、Huntington舞蹈病、中风、肌萎缩侧索硬化症(ALS)、外周神经病变和其他特征为神经元坏死或丧失的病症，无论是中枢的、外周的还是运动神经元；进一步优选，所述神经系统疾病包括但不限于糖尿病、AIDS或化疗相关的神经病变。
17.权利要求1所述的神经生长因子突变体用于制备有效减轻体重的药物中的用途。
18.权利要求1所述的神经生长因子突变体用于制备长效化神经生长因子的用途。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210214938.8A CN114671941B (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016101593037 | 2016-03-18 | ||
| CN201610159303 | 2016-03-18 | ||
| PCT/CN2017/077038 WO2017157326A1 (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
| CN202210214938.8A CN114671941B (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
| CN201780017019.9A CN109153709B (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780017019.9A Division CN109153709B (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114671941A true CN114671941A (zh) | 2022-06-28 |
| CN114671941B CN114671941B (zh) | 2023-09-26 |
Family
ID=59850520
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210214934.XA Active CN114671940B (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
| CN202210214942.4A Withdrawn CN114671942A (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
| CN201780017018.4A Active CN109071678B (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子融合蛋白、制备方法及其用途 |
| CN201780017019.9A Active CN109153709B (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
| CN202210214938.8A Active CN114671941B (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210214934.XA Active CN114671940B (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
| CN202210214942.4A Withdrawn CN114671942A (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
| CN201780017018.4A Active CN109071678B (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子融合蛋白、制备方法及其用途 |
| CN201780017019.9A Active CN109153709B (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US11213568B2 (zh) |
| EP (3) | EP4292649A3 (zh) |
| CN (5) | CN114671940B (zh) |
| DK (1) | DK3431507T3 (zh) |
| ES (1) | ES2966133T3 (zh) |
| HU (1) | HUE064504T2 (zh) |
| WO (2) | WO2017157326A1 (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017157326A1 (zh) * | 2016-03-18 | 2017-09-21 | 舒泰神（北京）生物制药股份有限公司 | 神经生长因子突变体 |
| CN113845583B (zh) * | 2020-06-28 | 2023-08-11 | 江苏中新医药有限公司 | 一种修饰的重组人神经生长因子及其制备方法 |
| JP2023551440A (ja) | 2020-11-19 | 2023-12-08 | 舒泰神（北京）生物製薬股フン有限公司 | 持効型神経成長因子ポリペプチド及びその用途 |
| CN115894705A (zh) * | 2021-09-30 | 2023-04-04 | 三生国健药业（上海）股份有限公司 | 一种β-NGF融合蛋白、其制备方法及用途 |
| WO2023088351A1 (zh) * | 2021-11-19 | 2023-05-25 | 舒泰神（北京）生物制药股份有限公司 | 神经生长因子在制备用于治疗或改善生殖系统疾病的药物中的用途 |
| EP4342485A1 (en) * | 2022-09-23 | 2024-03-27 | Dompe' Farmaceutici S.P.A. | Ngf for the treatment of spasticity |
| CN115813951B (zh) * | 2022-11-10 | 2023-07-21 | 北京昱龙盛世生物科技有限公司 | 转基因干细胞及其用于治疗失眠症或睡眠障碍的用途 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1698883A (zh) * | 2004-05-21 | 2005-11-23 | 舒泰神（北京）药业有限公司 | 神经生长因子在制备有效减轻体重的药物中的应用 |
| WO2008006893A1 (en) * | 2006-07-13 | 2008-01-17 | Lay Line Genomics S.P.A. | Muteins of hngf, therapeutic uses and pharmaceutical compositions |
| US7935671B2 (en) * | 1994-06-03 | 2011-05-03 | Genentech, Inc. | Pantropic neurotrophic factors |
| US20120141485A1 (en) * | 2010-12-01 | 2012-06-07 | Garcia-Martinez Leon F | Methods of preventing or treating pain using anti-ngf antibodies |
| CN102898514A (zh) * | 2011-07-28 | 2013-01-30 | 中国人民解放军军事医学科学院生物工程研究所 | 重组人神经生长因子缺失突变体及其制备方法和用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5349055A (en) | 1992-03-06 | 1994-09-20 | Persson Hakan B | Nerve growth factor having altered receptor binding specificities |
| US7452863B1 (en) | 1997-04-29 | 2008-11-18 | Genentech, Inc. | NGF variants |
| WO2005040335A2 (en) * | 2003-10-23 | 2005-05-06 | Monika Holmberg | A novel mutated nerve growth factor beta gene, proteins encoded thereby, and products and methods related thereto |
| ES2315842T3 (es) * | 2004-01-19 | 2009-04-01 | Nsgene A/S | Celulas terapeuticas humanas que secretan factor de crecimiento nervioso. |
| CN101260398B (zh) * | 2007-03-07 | 2013-06-05 | 舒泰神（北京）生物制药股份有限公司 | 神经生长因子基因定位改造动物及其制备方法和应用 |
| EP2231179A2 (en) | 2007-12-20 | 2010-09-29 | Cytos Biotechnology AG | Ngf conjugates and uses thereof |
| MX2012005791A (es) | 2009-11-19 | 2012-07-03 | Merck Serono Sa | Anticuerpos humanizados contra el receptor alfa de la interleucina 22 humana. |
| CN103159843B (zh) | 2011-12-19 | 2014-11-05 | 中国科学院生物物理研究所 | 具有低免疫副作用的神经生长因子突变体的制备方法及其药物应用价值 |
| CN103376248B (zh) | 2012-04-26 | 2016-06-01 | 舒泰神（北京）生物制药股份有限公司 | 神经生长因子活性定量测定方法 |
| CN105273087A (zh) * | 2014-07-14 | 2016-01-27 | 复旦大学 | NGF-Fc融合蛋白及其制备方法 |
| WO2017157326A1 (zh) | 2016-03-18 | 2017-09-21 | 舒泰神（北京）生物制药股份有限公司 | 神经生长因子突变体 |
-
2017
- 2017-03-17 WO PCT/CN2017/077038 patent/WO2017157326A1/zh active Application Filing
- 2017-03-17 CN CN202210214934.XA patent/CN114671940B/zh active Active
- 2017-03-17 EP EP23203486.8A patent/EP4292649A3/en active Pending
- 2017-03-17 CN CN202210214942.4A patent/CN114671942A/zh not_active Withdrawn
- 2017-03-17 CN CN201780017018.4A patent/CN109071678B/zh active Active
- 2017-03-17 EP EP17765868.9A patent/EP3431494B1/en active Active
- 2017-03-17 CN CN201780017019.9A patent/CN109153709B/zh active Active
- 2017-03-17 DK DK17765867.1T patent/DK3431507T3/da active
- 2017-03-17 HU HUE17765867A patent/HUE064504T2/hu unknown
- 2017-03-17 US US16/085,977 patent/US11213568B2/en active Active
- 2017-03-17 EP EP17765867.1A patent/EP3431507B1/en active Active
- 2017-03-17 CN CN202210214938.8A patent/CN114671941B/zh active Active
- 2017-03-17 WO PCT/CN2017/077025 patent/WO2017157325A1/zh active Application Filing
- 2017-03-17 ES ES17765867T patent/ES2966133T3/es active Active
- 2017-03-17 US US16/085,984 patent/US11883464B2/en active Active
-
2021
- 2021-11-19 US US17/455,870 patent/US20220088136A1/en not_active Abandoned
-
2023
- 2023-02-07 US US18/165,801 patent/US20230241169A1/en active Pending
- 2023-12-11 US US18/535,927 patent/US20240131114A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7935671B2 (en) * | 1994-06-03 | 2011-05-03 | Genentech, Inc. | Pantropic neurotrophic factors |
| CN1698883A (zh) * | 2004-05-21 | 2005-11-23 | 舒泰神（北京）药业有限公司 | 神经生长因子在制备有效减轻体重的药物中的应用 |
| WO2008006893A1 (en) * | 2006-07-13 | 2008-01-17 | Lay Line Genomics S.P.A. | Muteins of hngf, therapeutic uses and pharmaceutical compositions |
| US20120141485A1 (en) * | 2010-12-01 | 2012-06-07 | Garcia-Martinez Leon F | Methods of preventing or treating pain using anti-ngf antibodies |
| CN102898514A (zh) * | 2011-07-28 | 2013-01-30 | 中国人民解放军军事医学科学院生物工程研究所 | 重组人神经生长因子缺失突变体及其制备方法和用途 |
Non-Patent Citations (1)
| Title |
|---|
| 舒泰神(北京)药业有限公司: "促进神经损伤恢复药物-注射用鼠神经生长因子(一)", 《眼科》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109071678B (zh) | 2022-05-20 |
| CN114671941B (zh) | 2023-09-26 |
| WO2017157326A1 (zh) | 2017-09-21 |
| EP4292649A2 (en) | 2023-12-20 |
| US11213568B2 (en) | 2022-01-04 |
| CN114671940B (zh) | 2023-09-26 |
| HUE064504T2 (hu) | 2024-03-28 |
| ES2966133T3 (es) | 2024-04-18 |
| US20240131114A1 (en) | 2024-04-25 |
| CN109153709B (zh) | 2022-05-27 |
| CN109153709A (zh) | 2019-01-04 |
| US20200331977A1 (en) | 2020-10-22 |
| US11883464B2 (en) | 2024-01-30 |
| EP4292649A3 (en) | 2024-02-21 |
| EP3431507B1 (en) | 2023-11-22 |
| EP3431494A1 (en) | 2019-01-23 |
| CN114671940A (zh) | 2022-06-28 |
| US20190105373A1 (en) | 2019-04-11 |
| US20220088136A1 (en) | 2022-03-24 |
| CN114671942A (zh) | 2022-06-28 |
| EP3431494B1 (en) | 2024-05-01 |
| US20230241169A1 (en) | 2023-08-03 |
| EP3431507A1 (en) | 2019-01-23 |
| CN109071678A (zh) | 2018-12-21 |
| DK3431507T3 (da) | 2024-01-02 |
| EP3431494A4 (en) | 2020-01-01 |
| WO2017157325A1 (zh) | 2017-09-21 |
| EP3431507A4 (en) | 2019-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109153709B (zh) | 神经生长因子突变体 | |
| CN112409471B (zh) | 低痛神经生长因子突变体 | |
| JP2003159083A (ja) | 新規な神経栄養因子 | |
| CN103952388B (zh) | 重组的弹性蛋白酶蛋白质及其制备方法和用途 | |
| CN109111517B (zh) | 一种经修饰的生长分化因子及其制备方法和应用 | |
| CN100457778C (zh) | 睫状神经营养因子(cntf)突变体及其生产方法和其用途 | |
| CN112500472B (zh) | 一种猫ω干扰素突变体及其制备方法和应用 | |
| CN108218978B (zh) | 一种重组白细胞介素18及其制备方法与应用 | |
| US20220088139A1 (en) | Nerve growth factor mutant | |
| WO2008120263A2 (en) | Prokineticins receptors antagonists, derivatives and uses thereof | |
| EP3967706A1 (en) | Aav mutant that efficiently infects supporting cells | |
| CN101897953A (zh) | 无创性高穿透性表皮生长因子及其应用 | |
| CN108864300A (zh) | 鸡白蛋白-干扰素α-白介素2融合蛋白、制备方法及其编码基因、一种鸡长效干扰素 | |
| CN1035192C (zh) | 一种重组葡激酶的制备方法 | |
| CN114480320B (zh) | 重组夜猴尿酸酶及其应用 | |
| WO2023123776A1 (en) | Growth hormone fusion protein and preparation method and use thereof | |
| CN109689079A (zh) | 牛成纤维细胞生长因子21和乳畜中的酮病 | |
| CN109810983B (zh) | 猪IFN-γ的优化基因和采用该优化基因制备猪IFN-γ的方法及其注射液和应用 | |
| JPH09510358A (ja) | 脳−誘導神経栄養因子（ｂｄｎｆ）をコードする組み換えアデノウィルス | |
| CN115710307A (zh) | 蝎毒素及其突变体在抗癫痫中的应用 | |
| CN114874316A (zh) | 一种水溶性胶原蛋白及其应用 | |
| JP2001511641A (ja) | インターロイキン―５のアンタゴニスト | |
| CN117645661A (zh) | 一种聚乙二醇修饰的il-21衍生物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |